Financière de Tubize SAの配当性向
Financière de Tubize SAの配当性向は何ですか。
Financière de Tubize SAの配当性向は16.57%です。
配当性向の定義は何ですか。
配当性向は、株主への配当で支払われる利益の割合です。
The payout ratio is calculated by dividing the dividends paid out by the net earnings for a certain period. It is usually expressed as a percentage. The part of the earnings not paid to investors is left for investment to provide for future earnings growth. Investors seeking high current income and limited capital growth prefer companies with high payout ratio. However investors seeking capital growth may prefer lower payout ratio because capital gains are taxed at a lower rate. High growth firms in early life generally have low or zero payout ratios. As they mature, they tend to return more of the earnings back to investors.
EURONEXTのセクタHealth Careにおける配当性向の企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似の配当性向
- Brigade Enterprisesの配当性向は16.43%です。
- Leifheit AGの配当性向は16.49%です。
- Indraprastha Gasの配当性向は16.50%です。
- UFP Industries Incの配当性向は16.52%です。
- Louisiana-Pacificの配当性向は16.53%です。
- Halliburton Coの配当性向は16.56%です。
- Financière de Tubize SAの配当性向は16.57%です。
- Central Valley Community Bancorpの配当性向は16.59%です。
- Advanced Industriesの配当性向は16.60%です。
- Ovintiv Incの配当性向は16.60%です。
- Indian Oilの配当性向は16.64%です。
- JK Paperの配当性向は16.64%です。
- Pro Real Estate Investment Trustの配当性向は16.65%です。